News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
521,440 Results
Type
Article (12236)
Company Profile (145)
Press Release (509059)
Multimedia
Podcasts (33)
Webinars (9)
Section
Business (175471)
Career Advice (373)
Deals (27040)
Drug Delivery (41)
Drug Development (57566)
Employer Resources (20)
FDA (10868)
Job Trends (9397)
News (254033)
Policy (21851)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (702)
Accelerated approval (35)
ADA (21)
Adcomms (9)
Allergies (119)
Alliances (35322)
ALS (146)
Alzheimer's disease (1077)
Antibody-drug conjugate (ADC) (416)
Approvals (11650)
Artificial intelligence (421)
ASCO (199)
Autoimmune disease (266)
Automation (38)
Bankruptcy (278)
Belgium (8)
Best Places to Work (7561)
BIO (38)
Biologics (49)
BIOSECURE Act (3)
Biosimilars (166)
BioSpace Insights (26)
Biotechnology (92)
Bispecific (25)
Bladder cancer (173)
Brain cancer (52)
Breast cancer (629)
Cancer (4615)
Cardiovascular disease (300)
Career advice (318)
Career pathing (6)
CAR-T (205)
CDC (7)
CDMO (42)
Celiac Disease (3)
Cell therapy (572)
Cervical cancer (38)
Clinical research (52350)
Collaboration (1489)
Commercialization (29)
Compensation (1619)
Complete response letters (43)
COVID-19 (1334)
CRISPR (77)
C-suite (942)
Cystic fibrosis (100)
Data (6846)
Decentralized trials (1)
Denatured (5)
Depression (113)
Dermatology (110)
Diabetes (427)
Diagnostics (4543)
Digital health (46)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (201)
Drug pricing (84)
Drug shortages (7)
Duchenne muscular dystrophy (199)
Earnings (77029)
Editorial (9)
Employer branding (5)
Employer resources (23)
ESMO (255)
Events (92805)
Executive appointments (803)
Eye disease (3)
FDA (14054)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (1)
Friedreich's ataxia (22)
Frontotemporal dementia (27)
Funding (1117)
Gene editing (149)
Generative AI (20)
Gene therapy (391)
GLP-1 (455)
Government (2530)
Grass and pollen (3)
Guidances (304)
Healthcare (10587)
Hematology (105)
HIV (62)
Huntington's disease (34)
Idiopathic pulmonary fibrosis (7)
IgA nephropathy (85)
Immunology and inflammation (143)
Immuno-oncology (86)
Indications (199)
Infectious disease (1572)
Inflammatory bowel disease (153)
Inflation Reduction Act (8)
Influenza (94)
Intellectual property (282)
Interviews (47)
IPO (12904)
IRA (26)
Job creations (2242)
Job search strategy (301)
JPM (7)
Kidney cancer (25)
Kidney disease (91)
Labor market (6)
Layoffs (108)
Leadership (4)
Legal (5649)
Licensing (58)
Liver cancer (65)
Longevity (28)
Lung cancer (707)
Lung diease (10)
Lymphoma (318)
Machine learning (34)
Management (6)
Manufacturing (725)
Marketing (23)
MASH (127)
Medical affairs (3)
Medical device (9393)
Medtech (9592)
Mergers & acquisitions (15272)
Metabolic disorders (894)
mRNA (103)
Multiple sclerosis (129)
Multispecific (4)
NASH (4)
Netherlands (8)
Neurodegenerative disease (264)
Neuropsychiatric disorders (47)
Neuroscience (2128)
Neurotech (2)
NextGen: Class of 2026 (3390)
Non-profit (1272)
Now hiring (4)
Obesity (312)
Opinion (54)
Ovarian cancer (205)
Pain (210)
Pancreatic cancer (250)
Parkinson's disease (229)
Partnered (12)
Patents (573)
Patient advocacy (3)
Patient recruitment (594)
Patient selection (52)
Peanut (42)
People (43916)
Peptides (18)
Pharmaceutical (32)
Pharmacy benefit managers (11)
Phase 1 (16494)
Phase 2 (23016)
Phase 3 (16714)
Pipeline (9200)
Policy (90)
Postmarket research (1791)
Preclinical (6868)
Press Release (38)
Prostate cancer (243)
Psychedelics (18)
Radiopharmaceuticals (258)
Rare diseases (713)
Real estate (3312)
Recruiting (11)
Regenerative medicine (13)
Regulatory (17689)
Reports (29)
Research institute (782)
Resumes & cover letters (48)
Rett syndrome (47)
RNA editing (10)
RSV (61)
Schizophrenia (129)
Series A (190)
Series B (135)
Service/supplier (6)
Sickle cell disease (70)
Special edition (6)
Spinal muscular atrophy (98)
Sponsored (9)
Startups (2181)
Stem cells (2)
Stomach cancer (9)
Substance use disorders (16)
Supply chain (68)
Tariffs (39)
The Weekly (27)
Vaccines (553)
Venture capital (28)
Weight loss (140)
Wet AMD (3)
Women's health (110)
Worklife (2)
Date
Today (28)
Last 7 days (528)
Last 30 days (1893)
Last 365 days (20680)
2026 (17199)
2025 (20626)
2024 (24537)
2023 (28197)
2022 (37501)
2021 (40747)
2020 (36821)
2019 (26073)
2018 (19668)
2017 (20473)
2016 (19645)
2015 (25841)
2014 (22715)
2013 (18960)
2012 (20991)
2011 (21207)
2010 (21056)
Location
Africa (321)
Alabama (81)
Alaska (3)
Arizona (329)
Arkansas (12)
Asia (20618)
Australia (2721)
California (13121)
Canada (3992)
China (757)
Colorado (542)
Connecticut (469)
Delaware (323)
Europe (33341)
Florida (1982)
Georgia (415)
Hawaii (3)
Idaho (49)
Illinois (822)
India (78)
Indiana (409)
Iowa (25)
Japan (490)
Kansas (104)
Kentucky (33)
Louisiana (29)
Maine (29)
Maryland (1395)
Massachusetts (8713)
Michigan (323)
Minnesota (616)
Mississippi (5)
Missouri (102)
Montana (21)
Nebraska (13)
Nevada (136)
New Hampshire (66)
New Jersey (3161)
New Mexico (12)
New York (3116)
North Carolina (1423)
North Dakota (4)
Northern California (6661)
Ohio (332)
Oklahoma (15)
Oregon (21)
Pennsylvania (2506)
Puerto Rico (24)
Rhode Island (33)
South America (507)
South Carolina (81)
South Dakota (1)
Southern California (5453)
Tennessee (134)
Texas (2217)
United States (43458)
Utah (398)
Vermont (2)
Virginia (177)
Washington D.C. (45)
Washington State (1010)
West Virginia (1)
Wisconsin (83)
Wyoming (1)
521,440 Results for "astrazeneca canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research
October 27, 2026
·
4 min read
Breast cancer
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.
September 14, 2026
·
2 min read
·
Tristan Manalac
Approvals
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significantly larger opportunity” for the drug.
September 8, 2026
·
2 min read
·
Tristan Manalac
Earnings
AstraZeneca employs $1.5B cost savings to reinvest back into growth
“You don’t spend one and a half billion dollars without creating jobs,” AstraZeneca CEO Pascal Soriot said as the pharma announced a new cost savings program alongside third quarter earnings.
October 30, 2026
·
3 min read
·
Annalee Armstrong
Artificial intelligence
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated amyloid cardiomyopathy.
October 15, 2026
·
1 min read
·
Annalee Armstrong
Immunology and inflammation
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.
August 28, 2026
·
2 min read
·
Tristan Manalac
Business
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
July 22, 2026
·
4 min read
·
Nick Paul Taylor
Manufacturing
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.
August 10, 2026
·
2 min read
·
Nick Paul Taylor
Lung cancer
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
August 17, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote
An FDA advisory committee recently voted against approving AstraZeneca’s oral SERD drug camizestrant for certain patients with advanced breast cancer. It is unclear when the new target action date for the drug will be.
May 27, 2026
·
4 min read
·
Tristan Manalac
1 of 52,144
Next